A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)

Study identifier:D3562C00076

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A 104-Week, Open-label, Multi-centre, Phase IIIb Study Evaluating the Effect of Treatment with Rosuvastatin 40 mg on Atherosclerotic Disease as Measured by Intravascular Ultrasound and Quantitative Coronary Angiography in Subjects Undergoing Coronary Angiography who have Coronary Artery Disease

Medical condition

Coronary Arteriosclerosis

Phase

Phase 3

Healthy volunteers

No

Study drug

Rosuvastatin calcium

Sex

All

Actual Enrollment

450

Study type

Interventional

Age

18 Years +

Date

Study Start Date: 01 Nov 2002
Primary Completion Date: 01 Nov 2005
Study Completion Date: 01 Nov 2005

Study design

Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Sponsors

AstraZeneca Pharmaceuticals

Collaborators

-

Inclusion and exclusion criteria